Vtesse’s Niemann-Pick C therapy awarded PIM status
An investigational therapy in development for the treatment of Niemann-Pick Type C1 disease (NPC) has been awarded Promising Innovative Medicine (PIM) status by the Medicines and Healthcare products Regulatory Agency.
Read More
